Released on: December 19, 2007, 2:03 pm

Press Release Author: GTCbio

Industry: Pharmaceuticals

Press Release Summary: Robert Copeland, VP of Biology, Oncology Center of
Excellence in Drug Discovery at GlaxoSmithKline to give keynote presentation at 5th
Cancer Drugs R&D conference on February 21-22, 2008 in Phoenix.

Press Release Body: MONROVIA, CA - Robert Copeland, VP of Biology, Oncology Center
of Excellence in Drug Discovery at GlaxoSmithKline to give keynote presentation at
5th Cancer Drugs R&D conference on February 21-22, 2008 in Phoenix.

Dr. Copeland will present on mechanism-driven approaches to molecularly targeted
cancer drug discovery.

Oncology drug discovery at GlaxoSmithKline is focused on molecularly targeted
therapeutics for the treatment of cancer and for cancer supportive care indications.
A guiding principle of the company's approach is that a detailed, mechanistic
understanding of pathobiology and of drug action - at the molecular, cellular and
organismal level - is essential for effective drug discovery. Towards this end
GlaxoSmithKline has built a discovery organization that encompasses robust
biochemical, cellular biological and in vivo pharmacological interrogation of drug
candidates. Examples of the application of these approaches to several cancer
drug-seeking efforts will be presented at the conference.

Jeffrey Hanke, Vice President of Cancer Research at AstraZeneca, will also give a
keynote presentation.

Dr. Hanke will present on developing new therapeutics for the treatment of cancer.
He will discuss challenges and opportunities within the field of cancer drugs.

AstraZeneca's cancer discovery research operations are considered a top priority
within the company. AstraZeneca also focuses on novel approaches to cancer
prevention and therapy. The company is optimistic about future compounds and drugs
for the treatment of cancer.

The 5th Cancer Drugs Research & Development conference features presentations on the
successes and setbacks of modern cancer drugs, new drug compounds and future drugs
for the treatment and prevention of cancer, cancer drug development in clinical
trials and new drug delivery methods. For more information, visit www.gtcbio.com.


Web Site: http://gtcbio.com/Allconferences.aspx

Contact Details: ABOUT GTCbio

GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government
organizations, and the financial community.

GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company
founded in 2002.

Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com

GTCbio
434 W Foothill Blvd.
Monrovia, CA 91016